ZIOPHARM Oncology, Inc. , a biopharmaceutical company focused on the development and commercialization of new cancer therapies, announced today results demonstrating the potent anti-tumor and anti-cancer stem cell effects of Ad-RTS-IL-12 in a glioma model, and in other preclinical and clinical settings.
http://ift.tt/StL8dT
http://ift.tt/StL8dT
No comments:
Post a Comment